prescription behavior surveillance using pdmp data dagan wright, phd, msph (oregon health authority)...
TRANSCRIPT
Prescription Behavior Surveillance Using PDMP Data
Dagan Wright, PhD, MSPH (Oregon Health Authority)Denise Penone, PhD (New York City Department of Health)
Special thanks and acknowledgement to Len Paulozzi who could not attend as all contributors
Outline of the PDMP Talk
• What is PMP or PDMP?• Why so important?• What are general characteristics and data
elements?• What are questions that can be answered?• Examples of data• Examples of outreach and evaluation
What is PMP or PDMP?• Tool utilized for reducing prescription drug misuse and diversion
– Drug Epidemic Warning System– Drug Diversion & Fraud Investigative Tool
• Public Health Surveillance tool to collect, monitor, and analyze dispensing data– Avoidance of Drug Interactions– Patient Care Tool– Identification & Prevention of “Doctor Shopping”*
• Data now can used to support states’ efforts in education, research, quality assurance (better healthcare), enforcement and abuse prevention
• Not meant to infringe on the legitimate prescribing of controlled substances
*Doctor Shopping: Practice of obtaining multiple controlled substance prescriptions from multiple doctors
Source: http://www.pmpalliance.org/content/prescription-monitoring-frequently-asked-questions-faq
Why so Important?
5
Opioid analgesic overdose deaths increased 65%
Opioid analgesic overdose deaths, NYC, 2005-2011
Source: New York City Office of the Chief Medical Examiner & New York City Department of Health and Mental Hygiene 2005-2011
2005 2006 2007 2008 2009 2010 20110
50
100
150
200
250
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
130 152 131 137 158 173 220
2.02.3
2.02.0
2.42.6
3.3
Number of opioid analgesic overdose deaths
Age-adjusted opioid analgesic rates per 100,000 New Yorkers
Nu
mb
er
Ag
e-A
dju
ste
d R
ate
pe
r 1
00
,00
0
Oregon Drug Related TrendsCounts and rates/100,00
72000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
0
50
100
150
200
250
300
350
400
450
0
2
4
6
8
10
12
Unintentional drug poisoning deaths by year and drug type, Oregon 2000-2011
CocaineHeroinPrescription opioidsRate of drug poisoning
Coun
t
Unad
just
ed ra
te/1
00,0
00
9
Methadone Death Rates Parallel Methadone Sales
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
0
1000
2000
3000
4000
5000
6000
1999 2000 2001 2002 2003 2004 2005 2006 Rat
e o
f m
eth
ado
ne
-ass
oci
ate
d p
ois
on
ing
de
ath
s p
er
10
0,00
0 pe
rso
ns
Gra
ms
me
thad
on
e s
old
pe
r 1
00,0
00
pe
rso
ns
Note: grams sold on left axis, death rate on right axis
Retail distribution of methadone in Oregon and poisoning mortality rate asociated with methadone in Oregon, 1999-2006
Grams sold/100,000 population
Methadone death rate
Sources: US Dept. of Justice, Drug Enforcement Administration, Of f ice of Diversion Control, Automation of Reports and Consolidated Orders System (ARCOS); Oregon Center for Health Statistics mortality data f iles. Includes unintetnional and undetermined intent deaths.
Oregon Public Health Division- Injury Prevention Program
10
More Drug Overdose Deaths than Motor Vehicle Crash Deaths
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 20110.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
Unintentional drug overdose and motor vehicle death rates, Oregon 2000-2011
Unintentional drug overdoseMotor vehicle crash
Source: Oregon Vital Records
Year
Oregon Hospitalization Rate/10,000 residents
11
15-24 25-34 35-44 45-54 55-64 65-74 75-84 85+02468
101214161820
Prescrip. opioids no methadoneMethadoneBenzodiazepinesAntiepileptic, sedative-hypnotic, an-tidepressantPsychostimulats
Age Group
Unad
just
ed ra
te/1
00,0
00
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 20110.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
Psychostimulants with abuse potentialOther,unspecified drugsHeroinPrescrip opioidsBenzodiazepinesMethadoneAlcoholAntidepressants,etc,psychotropic drugs NEC
Year
Unad
just
ed ra
te/1
00,0
00
What are General Characteristics and Data Elements?
12
PDMP: General Characteristics
• Typically require monthly or bi-weekly reporting– Some States require weekly reporting i.e., Florida, Oregon– Oklahoma, requires reporting at time of sale
• Reactive vs. Proactive– Reactive: Generate solicited reports only in response to a specific
inquiry – Proactive: Generate unsolicited reports whenever suspicious or
potentially at risk to the patient behavior is detected• Drug Schedules Monitored by states:
– 24 collect Schedules II -V– 17 collect Schedules II –IV– 1 collect Schedule II only– 2 collect Schedules II & III
Source: http://www.simeoneassociates.com/simeone3.pdf
PDMP: Information Collected
• Patient identification– Name & Address– DOB & Gender
• Prescriber Information & Dispenser Information – DEA number
• Drug Information– National Drug Code (NDC) Info:
• Name• Type • Strength • Manufacturer
– Quantity & date dispensed
Source: http://www.pmpalliance.org/
PDMP Attributes As a Surveillance System
• Simplicity: single data source, few data elements, drug code (NDC) is complicated
• Flexibility: limited fields• Data quality: insurance and system error checks• Acceptability: mandatory
See: Lee et al, eds., Principles and Practice of Public Health Surveillance, 3rd edition, 2010.
PDMP Attributes As a Surveillance System
• Sensitivity: high, required by law• Predictive value positive: metrics untested• Representativeness: population-based• Timeliness: days to weeks• Stability: in most cases operating for years• Cost: support for many is inadequate for most PDMPs
– Other sources Oregon uses a provider licensing fee to support the PDMP
See: Lee et al, eds., Principles and Practice of Public Health Surveillance, 3rd edition, 2010.
Model Act 2010 RevisionData Elements for PDMPs
Prescription Number, Date issued by prescriber, Date filled, New or refill, Number of refills, State-issued serial number (optional)
Drug NDC code for drug, Quantity dispensed, Days’ supply dispensed
Model Act 2010 RevisionData Elements for PDMPs
Patient Identification number Name, Address, Date of birth, Sex Source of payment Name of person who receives prescription if other than patient
Prescriber Identification number
Dispenser Identification number
Descriptive Measures: Prescription Counts
• Specific compound, formulation• Drug class
– Opioids, benzodiazepines, stimulants, etc.– All extended-release formulations of opioids– Class within a schedule, e.g., Schedule II opioids
• Daily dosage of an opioid prescription
Questions that can be Answered
20
Descriptive Measures: Denominators
• Person, e.g., rx per 1,000 people (most common)
• Patient, e.g., rx per 1,000 patients• Prescriber, e.g., mean daily dose/prescriber• Pharmacy, e.g., rx/pharmacy
Time period is specified: e.g., in 2012, in past quarter
Descriptive Measures: “By” Variables
• Patient sex, age group • Patient/prescriber/pharmacy by county or zip
code• Month, year (prescribed or dispensed)• Prescriber specialty (requires linkage based on
prescriber number)• Source of payment (where collected)• Patient type, e.g., opioid-naive
Risk Measures: Daily Dose for Opioids
• Converted to morphine milligram equivalents (MME)• Usually categorized, e.g.,
– High, e.g., >100 MME/day– Going beyond specific dosing guidelines
• e.g., more than 30 mg of methadone per day for an opioid-naïve person
• Also quantified by measures of central tendency: mean, median , quartiles dose
• SAS coding to do MME conversions available from CDC
Examples of Data
24
Number of Patients Receiving Opioid Dosages > 100 MME/day, Tennessee, 2007‒2011
Num
ber o
f Pati
ents
Baumblatt J. Prescription Opioid Use and Opioid-Related Overdose Death TN, 2009–2010, CDC EIS Tuesday Morning Seminar, 1/8/2013
Opioid Prescriptions Filled by Staten Islanders Are More Frequently High Dose
2008 2009 2010 2011 20120%
5%
10%
15%
20%
25%
% of opioid prescriptions filled that are high dose, by borough of residence
Staten IslandBronxManhattanBrooklynQueens
% o
f opi
oid
pres
crip
tions
that
are
for >
100
m
orph
ine
equi
vale
nt m
gs o
f opi
oids
Schedule II opioids + hydrocodone, New York State Prescription Drug Monitoring Program
27
Number of people/1,000 residents receiving an opioid Oct 1, 2011 to March 31, 2012
28
Number of people/1,000 residents receiving an opioid and benzodiazepineOct 1, 2011 to March 31, 2012
29
Number of people/10,000 residents using 4 or more prescribers and 4 or more pharmacies
Oct 1, 2011 to March 31, 2012
Rates of Unintentional Poisoning Mirrors Rates of Dispensed Prescriptions
Source: http://www.nyc.gov/html/doh/downloads/pdf/epi/epi-data-brief.pdf
Use of PMP Data by MA Dept. of Public Health
“Shopping” as a portion of all prescriptions Overdoses in ED Data
Slide provided courtesy of Peter Kreiner, PMP Center of Excellence at Brandeis. Doctor shopping, the questionable activity, was defined as 4+ prescriber s and 4+ pharmacies for CSII in six months.
Measures of “Shopping” or “Multiple Provider Episodes”
Author (year) Drug No. of Prescribers
No. of Pharmacies
Rx Overlap
TimePeriod
Hall (2008) Any CS 5+ NA NA 1 yr
Peirce (2012) Any CS 4+NA
NA4+
NANA
6 mo6 mo
Ohio DOH (2010)
Opioid Avg of 5+ NA NA Over 3 yrs
Gilson (2010, 2012)
“Same medication”
2+ 2+ NA 30 d
Katz (2010) Any CSII 4+ 4+ NA 1 yr
Cepeda (2012) Opioid 2+ 3+ 1+ day 18 mo
BJA criteria CSII-IV 5+ 5+ NA 3 mo.
Patient vs. Provider Metrics?
• Top 1% of prescribers based on number of prescriptions might account for 33% of the morphine equivalents (MME) in your state.(1)
• Top 1% of patients might account for 40% of MME.(2)
1. Swedlow 2011; 2. Edlund 2010
15% of prescribers write 82% of opioid analgesic prescriptions
Prescribers Prescriptions0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
49%
2%
36%
15%
14%
51%
1%
31%
Very Frequent Prescribers530-10,185 RX/year
Frequent Pre-scribers50-529 RX/year
Occasional Prescribers4-49 RX/year
Rare Prescribers1-3 RX/year
Prescribing frequency
Prescriptions filled by NYC residents, 2010
15%
82%
Per
cen
t
Source: New York State Department of Health, Bureau of Narcotic Enforcement, Prescription Drug Monitoring Program, 2008-2010 34
Distribution of CS II-IV prescriptions to prescribers, Oregon, 1/12 to 9/12
% of Prescribers
4 4
92
% of CS Prescriptions
6019
21
Oregon Health Authority. Prescription Drug Dispensing in Oregon, October 1, 2011 – March 31, 2012
Examples of Outreach and Evaluation
36
Patient vs. Provider Metrics?
• 100 patients in the PMP for every prescriber
• It takes roughly 100 times more effort to address the same fraction of problematic prescriptions.
• For interventions, provider case-finding is preferred based on efficiency.
38
1st Evaluation of Oregon PDMP soon followed by NIH study – survey use
• 65% say it is very helpful to monitor patients’ prescriptions for controlled substances
• 64% report it is very helpful to control “doctor shopping”
• 78% have spoken with patient about controlled substance use after using system
• 59% reduced or eliminated prescriptions for a patient after using system
• 49% contacted other providers or pharmaciesSource: Oregon Prescription Drug Monitoring Program Evaluation
• Avoid prescribing opioids for chronic non-cancer, non-end-of-life pain• E.g. low back pain, arthritis, headache, fibromyalgia
• When opioids are warranted for acute pain, 3-day supply usually sufficient
• Avoid whenever possible prescribing opioids in patients taking benzodiazepines
• If dosing reaches 100 MED, reassess and reconsider other approaches to pain management
NYC Opioid Treatment Guidelines
References Cited• Cepeda, M., D. Fife, et al. (2012). "Assessing opioid shopping behavior." Drug Safety. • Edlund, M. J., B. C. Martin, et al. (2010). "Risks for opioid abuse and dependence among recipients of chronic opioid
therapy: results from the TROUP study." Drug Alcohol Depend 112(1-2): 90-98.• Forrester, M. B. (2011). "Ingestions of hydrocodone, carisoprodol, and alprazolam in combination reported to Texas poison
centers." Journal of Addictive Diseases 30: 110-115.• Hall, A. J., J. E. Logan, et al. (2008). "Patterns of abuse among unintentional pharmaceutical overdose fatalities." JAMA 300:
2613-2620.• Katz, N., L. Panas, et al. (2010). "Usefulness of prescription monitoring programs for surveillance---analysis of Schedule II
opioid prescription data in Massachusetts, 1996--2006." Pharmacoepidemiol Drug Safety 19: 115-123.• Ohio Department of Health. (2010). "Epidemic of prescription drug overdoses in Ohio." Retrieved September 1, 2010, from
http://www.healthyohioprogram.org/diseaseprevention/dpoison/drugdata.aspx.• Peirce, G., M. Smith, et al. (2012). "Doctor and pharmacy shopping for controlled substances." Med Care.• Swedlow, A., J. Ireland, et al. (2011). Prescribing patterns of schedule II opioids in California Workers' Compensation,
California Workers' Compensation Institute.• White, A. G., H. G. Birnbaum, et al. (2009). "Analytic models to identify patients at risk for prescription opioid abuse." Am J
Manag Care 15(12): 897-906.• Wilsey, B. L., S. M. Fishman, et al. (2010). "Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants,
and anorectics." Drug Alcohol Depend 112: 99-106.